NAGIOS: RODERIC FUNCIONANDO

Pharmacogenetics in Neuroblastoma: What Can Already Be Clinically Implemented and What Is Coming Next?

Repositori DSpace/Manakin

IMPORTANT: Aquest repositori està en una versió antiga des del 3/12/2023. La nova instal.lació está en https://roderic.uv.es/

Pharmacogenetics in Neuroblastoma: What Can Already Be Clinically Implemented and What Is Coming Next?

dc.contributor.author	Olivera, Gladys
dc.contributor.author	Urtasun Erburu, Andrea
dc.contributor.author	Sendra Gisbert, Luis
dc.contributor.author	Aliño Pellicer, Salvador F.
dc.contributor.author	Yáñez Peralta, Yania
dc.contributor.author	Segura, Vanessa
dc.contributor.author	Gargallo, Pablo
dc.contributor.author	Berlanga Charriel, Pablo
dc.contributor.author	Castel Sánchez, Victoria
dc.contributor.author	Cañete Nieto, Adela
dc.contributor.author	Herrero Cervera, María José
dc.date.accessioned	2022-05-18T14:45:55Z
dc.date.available	2022-05-18T14:45:55Z
dc.date.issued	2021
dc.identifier.citation	Olivera, Gladys Urtasun Erburu, Andrea Sendra Gisbert, Luis Aliño Pellicer, Salvador F. Yáñez Peralta, Yania Segura, Vanessa Gargallo, Pablo Berlanga Charriel, Pablo Castel Sánchez, Victoria Cañete Nieto, Adela Herrero Cervera, María José 2021 Pharmacogenetics in Neuroblastoma: What Can Already Be Clinically Implemented and What Is Coming Next? International Journal Of Molecular Sciences 22 18 9815
dc.identifier.uri	https://hdl.handle.net/10550/82837
dc.description.abstract	Pharmacogenetics is one of the cornerstones of Personalized Precision Medicine that needs to be implemented in the routine of our patients' clinical management in order to tailor their therapies as much as possible, with the aim of maximizing efficacy and minimizing toxicity. This is of great importance, especially in pediatric cancer and even more in complex malignancies such as neuroblastoma, where the rates of therapeutic success are still below those of many other types of tumors. The studies are mainly focused on germline genetic variants and in the present review, state of the art is presented: which are the variants that have a level of evidence high enough to be implemented in the clinic, and how to distinguish them from the ones that still need validation to confirm their utility. Further aspects as relevant characteristics regarding ontogeny and future directions in the research will also be discussed.
dc.language.iso	eng
dc.relation.ispartof	International Journal Of Molecular Sciences, 2021, vol. 22, num. 18, p. 9815
dc.subject	Farmacogenètica
dc.subject	Neuroblastoma
dc.subject	Quimioteràpia
dc.title	Pharmacogenetics in Neuroblastoma: What Can Already Be Clinically Implemented and What Is Coming Next?
dc.type	journal article	es_ES
dc.date.updated	2022-05-18T14:45:55Z
dc.identifier.doi	10.3390/ijms22189815
dc.identifier.idgrec	152235
dc.rights.accessRights	open access	es_ES